Articles On Paradigm Biopharmaceuticals (ASX:PAR)

Highlights Temporary ceasefire eases tensions, lifting Australian equities Tech and mining sectors lead gains while energy stocks fall Multiple companies report operational updates affecting share movements The ASX all ordinaries...

Paradigm Biopharma (ASX:PAR) has this week hit two big items out the park: first of all, hitting 50% recruitment in its Phase III osteoarthritis (OA) trial using iPPS, which allows the company to post interim efficacy data around August....

Highlights Healthcare stocks face rising short interest across the australian stock market Sector-wide sentiment impacted by recent earnings downgrades Long-term outlook supported by defensive positioning and innovation ASX health...

Highlights Healthcare stocks face heightened short-selling activity Sector weakness reflects shifting sentiment and company-specific factors Clinical updates and strategic moves shape outlook across key players Healthcare stocks f...

Paradigm Biopharma (ASX:PAR) has officially passed a milestone that gives investors in the company a ‘fast-track’ path to topline data from a Phase III trial investigating osteoarthritis using the company’s injectable drug iPPS. Listen...

Broker Ord Minnett names its healthcare stocks likely to be high flyers during the current market rout Paradigm Biopharmaceuticals is close to halfway there in its pivotal knee trial – and more than Livin’ on a Prayer Lumos awaits crucial...

Paradigm Biopharmaceuticals (ASX:PAR) has kicked off the screening process for participants with osteoarthritis ahead of the company’s Hong Kong-based Phase III trial using injectable pentosan polysulfate sodium (iPPS) – which, fun fact Fri...

The step from ‘science project’ to commercial asset in the ASX-listed biotechnology landscape is defined by a handful of key milestones, and none is more important than a Phase Three interim analysis, where the most dramatic value re-rating...

Welcome to the latest HotCopper Capital Compass, where we’ve this week spoken to Paradigm Biopharma (ASX:PAR) founder and managing director Paul Rennie about Paradigm arriving at its “pivotal” phase three trial, which will be examining outc...

Cynata tackles adult graft-versus-host disease, knee osteoarthritis and kidney disease Having acquired a Perth-based stem-cell program, Neuroscientific targets fistulating Crohn’s disease Following its breakthrough FDA approval, Mesoblast...

With more than seven million users on the HotCopper forums, every discussion and speculation can move Australian markets, which is why getting out in front of those trends is so important for any trader worth their salt. Listen to the Ho...

 Chemist Warehouse’s owner needs to show it has the growth prescription at its upcoming results Memphasys shares soar up to 25% on TGA approval Truscreen’s developing world rollout continues apace   Sigma Healthcare (ASX:SIG) has proved t...

Paradigm Biopharmaceuticals (ASX: PAR) has entered into a binding term sheet with AVet Health to co-develop and license a novel oral combination therapy for the treatment of osteoarthritis (OA) in companion animals. Listen to the HotCopp...

The FDA green lights Imricor’s Northstar ‘dashboard’ for controlling MRI-guided ablations Arovella and Painchek achieve FDA breakthroughs As well as soothing pain, Paradigm hopes its knee osteoarthritis drug mends joints   For the second...

Late-stage drug developer Paradigm Biopharmaceuticals (ASX:PAR) is preparing for a huge CY26 after landing a key recruitment milestone late last year, bringing in enough participants to hit its expected 25% goal. Listen to the HotCopper...

With the sun setting on another ‘issues rich’ year for ASX biotechs, Dr Boreham applies his stethoscope to the soaring highlights and cratering lowlights.   As usual we adopt the user-friendly A to Z format. If only drug, device and diagnos...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a decent gain. At the time of writing, the benchmark index is up 0.6% to 8,752.5 points. Four ASX shares that have failed to follow the market higher today are...

In this latest episode of HotCopper’s longform podcast From The Wire, Senior Markets Reporter Jonathon Davidson sat down with Paradigm Biopharmaceuticals (ASX:PAR) Chief Executive Officer (CEO) Paul Rennie. Listen to the HotCopper podca...

Who said free-to-air TV was in its death throes? When the Seven news network ran a piece about Paradigm Biopharmaceuticals’ (ASX:PAR) knee osteoarthritis (OA) drug candidate a few months ago, the company received around 700 emails from suff...

Paradigm Biopharma (ASX:PAR) has engaged a Scandinavian entity called Nordic Bioscience Clinical Development (NBCD) to expand the scope of its Phase 3 trial using its flagship product to treat osteoarthritis (OA) in knee joints. Listen...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

Biotechs are adopting ‘plan B’ strategies by purchasing complementary drug programs Antivirals house Biotron hopes to shake up the moribund anaesthetic drug sector Other companies with interesting diversions include Island Pharmaceuticals,...

It’s a fairly common occurrence for ASX-listed companies to start slowing down their operations as the holiday season draws near – but not so for Paradigm Pharmaceuticals (ASX:PAR), which only just last week both successfully recruited and...

If you have a high tolerance for risk, then it could be worth checking out the ASX stock in this article. That's because analysts at Bell Potter believe that its shares could rise materially over the next 12 months. Which ASX stock? The sto...

Pfizer has become the first Big Pharma company to sign a pricing deal with the Trump administration Bioxyne has the dope on likely US medical pot reforms Paradigm trial gets a knees-up with its first patient dosed The Trump administration...

On Tuesday, the S&P/ASX 200 Index (ASX: XJO) fought hard but ended the session in the red. The benchmark index fell 0.15% to 8,848.8 points. Will the market be able to bounce back from this on Wednesday? Here are five things to watch:...

Paradigm Biopharma (ASX:PAR) has officially kicked off its final-stage Phase 3 trial using injectable pentosan polysulfate sodium (iPPS) to treat patients with osteoarthritis (OA) in their knee joints, with randomised participants having no...

After a strategy revamp, Noxopharm is targeting inflammatory diseases – lupus in particular Affecting five million people, lupus has proved a tricky disease to tackle The company is pondering a phase II trial, most likely in skin lupus No...

Paradigm Pharmaceuticals (ASX:PAR) has been the clear winner on the HotCopper forums today after securing US$27 million in funding. (For a little more detail there, read my colleague Jonathon Davidson’s full write-up.) Listen to the HotC...

Highlights Bioxyne outpaces sector peers with performance in cannabis and health products Paradigm Biopharmaceuticals secures convertible note funding for late-stage trial Recce Pharmaceuticals and Botanix turn to debt as eq...

Bioxyne stars with a 720% gain in the 2024-25 year Paradigm shares soar 34% after $41 million convertible note deal Biotechs turn to debt funding The ASX biotech sector’s best EOFY performer has come from left field: the local and Europ...

Paradigm Biopharmaceuticals (ASX:PAR) shares were up nearly +25% in morning trades as the company unveiled a loan of around $41 million to advance its osteoarthritis clinical investigations. Listen to the HotCopper podcast for in-depth d...

Paradigm Biopharmaceutical (ASX: PAR) has opened the purse strings to pick up Proteobioactives Pty Ltd, which has been working on Pentacoxib, an early-stage oral candidate for minor to mild osteoarthritis. Listen to the HotCopper podcast...

The ASX200 traded flat yet again today, closely mimicking Wall Street. IT was heavily sold off in intra-day trade, followed by Real Estate and Industrials. Health Care and Financials were the only sectors substantially in the green. I...

Late-stage drug developer Paradigm (ASX:PAR) is trending today after adding a new oral combination IP to its osteoarthritis drug stable. The acquisition came after the company paid $500,000 to buy up Proteobioactives. Listen to the HotCo...

Paradigm Biopharmaceuticals will spend up to $16.5 million on an oral drug asset, but stays focused on its phase III knee trial Percheron enters headline $450 million cancer drug acquisition Neurizon goes from solid to liquid with its moto...

The S&P/ASX 200 Index (ASX: XJO) is out of form on Thursday and trading lower. At the time of writing, the benchmark index is down 0.2% to 8,540.7 points. Four ASX shares that are not letting that hold them back are listed below. Here's...

Paradigm Biopharmaceuticals (ASX:PAR) has acquired the exclusive global rights to develop – and, of course, commercialise – a novel oral combination of PPS and a COX-2 inhibitor designed to treat osteoarthritis and pains. Listen to the...

The market may be having a subdued start to the day but that hasn't stopped two ASX healthcare stocks from racing higher. Let's see why investors are bidding them higher today: Neuren Pharmaceuticals Ltd (ASX: NEU) The Neuren share price i...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Paradigm Biopharmaceuticals (ASX:PAR) has activated its first Australian clinical site as part of a Phase Three trial to assess injectable pentosan polysulfate sodium for the treatment of pain connected to knee osteoarthritis. Listen to...

Paradigm Biopharmaceuticals (ASX:PAR) is a late-stage drug development company working first and foremost to create a superior treatment for osteoarthritis. In the background, Paradigm also has a rare disease clinal asset for Mucopolysac...

Amplia says it has reached the requisite level of ‘partial responders’ in its mid-stage pancreatic cancer study Immutep reports “remarkable” response rates in a German-based lung cancer trial Paradigm wins US ethics approval for knee osteo...

Despite a late upturn, the ASX 200 closed 0.38% in the red on Thursday Blame factor 1: Trump and his 25% US auto import tariffs, set to come into play early April Blame factor 2: A Wall Street tech rout, which Trump had a hand in, too   ...

A cabal of ASX drug developers has defied the US gloom The healthcare jury’s out on new FDA head Dr Marty Makary Emvision’s Emu trial takes flight Amid the downbeat narrative about US healthcare policy and cuts to funding agencies, a ‘Mag...

Telix expects three more US product approvals this year Patrys switches to plan B Biotron’s do-or-die $500,000 capital raising   Analysts reckon Telix Pharmaceuticals (ASX:TLX) has only just started to reach its full potential, with three...

  Emyria says its ‘real world’ MDMA trial shows a “sustained improvement” in post-traumatic stress disorder (PTSD) symptoms Argenica says its traumatic brain injury candidate works in rats – and ferrets The biotech sector advanced to recor...

The S&P/ASX 200 rose 5% in January to reach a new record high Utilities was the only sector to fall in January with financials the top performer AusQuest tops January winners up 388% with discovery of a large-scale Peruvian copper pros...

  Paradigm launches loyalty options and piggyback options offer to reward shareholders for support Offer has potential to raise more than $110 million for the company Paradigm set to start phase III trial of PARA_OA_012 to treat knee OA in...